Trial Profile
A Phase 2, Open-label, Single-arm, Efficacy and Imaging Study of Oral Enzalutamide in Chemo-Naïve Patients With Progressive Prostate Cancer Who Have Failed Androgen Deprivation Therapy (Castration-resistant Prostate Cancer Patients)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2022
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 18 Feb 2021 Status changed from recruiting to completed.
- 17 Feb 2020 Planned End Date changed from 1 Jan 2021 to 1 Dec 2022.
- 17 Feb 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Jun 2022.